Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns negative
Q1 FY2026 change in working capital was -$101.88K, compared with $41.33K a year earlier. Trailing-twelve-month change in working capital was $269.66K. Over 3 fiscal years it compounded at +38.7% a year.
Context
- Change in working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly change in working capital holds near -$101.88K or moves back toward the trailing-twelve-month quarterly average of $67.42K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 412.88K USD
- Year-over-year change
- +13630.6%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 412.88K | +13630.6% |
| FY2024 | 2024-12-31 | 3.01K | -85.4% |
| FY2023 | 2023-12-31 | 20.56K | -86.7% |
| FY2022 | 2022-12-31 | 154.76K | +1251.4% |
| FY2021 | 2021-12-31 | (13.44K) | — |
Change in Working Capital vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's LTM Mar 2026 change in working capital of $269.66K is the smallest of the 2 companies compared; the peer median is $1.49M.
- Its year-over-year change of +874.2% is the lowest of 2, against a peer median of +1007.7%.
- Over three fiscal years its annual growth of +38.7% compares with a peer median of +11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.49M | +1007.7% | +11.5% | — | |
| LTM Mar 2026 | $269.66K | +874.2% | +38.7% | — | |
| Peer median (excluding LIXT) | $1.49M | +1007.7% | +11.5% | — | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.